个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Comorbidity defines asthmatic patients' risk of COVID-19 hospitalization: A global perspective

| 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Skevaki Chrysanthi[1,2,*1] * ; Chinthrajah R Sharon[3] ; Fomina Daria[4,5] ; Rohde Gernot[6,7,8] ; Cao Shu[3] ; He Ziyuan[3] ; Serdotetskova Sofia[5] ; Seidemann Christian[9] ; Achim Grunewaldt[6] ; Vengadeswaran Abisha[10] ; Xie Min[11] ; Karsonova Antonina[4] ; Karaulov Alexander[4] ; Nadeau Kari C[3] ; Chung Ho-Ryun[12] ; Renz Harald[1,2,4] ;
单位： [1]Institute of Laboratory Medicine and Pathobiochemistry, Philipps University Marburg [2]Universities of Giessen and Marburg Lung Center (UGMLC), Philipps University Marburg [3]Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford [4]Department of Clinical Immunology and Allergology, Laboratory of Immunopathology, Sechenov University, Moscow [5]Moscow City Research and Practical Center of Allergy and Immunology, Clinical State Hospital 52, Moscow Ministry of Healthcare [6]Department of Respiratory Medicine, University Hospital Frankfurt [7]CAPNETZ Foundation, Hannover [8]Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), the German Center for Lung Research, Hannover [9]Department of Data Integration Center, MIRACUM, Philipps University Marburg [10]Institute forMedical Informatics, Goethe University Frankfurt, University Hospital Frankfurt [11]Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan. [12]Institute for Medical Bioinformatics and Biostatistics, Philipps University Marburg
出处：
DOI： 10.1016/j.jaci.2022.09.039
ISSN：

关键词： Chronic airway in inflammation prevalence chronic obstructive pulmonary disease COPD public health SARS-CoV-2

摘要：
The global epidemiology of asthma among patients with coronavirus disease 2019 (COVID-19) presents striking geographic differences, defining prevalence zones of high and low co-occurrence of asthma and COVID-19.We aimed to compare asthma prevalence among hospitalized patients with COVID-19 in major global hubs across the world by applying common inclusion criteria and definitions.We built a network of 6 academic hospitals in Stanford (Stanford University)/the United States; Frankfurt (Goethe University), Giessen (Justus Liebig University), and Marburg (Philipps University)/Germany; and Moscow (Clinical Hospital 52 in collaboration with Sechenov University)/Russia. We collected clinical and laboratory data for patients hospitalized due to COVID-19.Asthmatic individuals were overrepresented among hospitalized patients with COVID-19 in Stanford and underrepresented in Moscow and Germany as compared with their prevalence among adults in the local community. Asthma prevalence was similar among patients hospitalized in an intensive care unit and patients hospitalized in other than an intensive care unit, which implied that the risk for development of severe COVID-19 was not higher among asthmatic patients. The numbers of males and comorbidities were higher among patients with COVID-19 in the Stanford cohort, and the most frequent comorbidities among these patients with asthma were other chronic inflammatory airway disorders such as chronic obstructive pulmonary disease.The observed disparity in COVID-19-associated risk among asthmatic patients across countries and continents is connected to the varying prevalence of underlying comorbidities, particularly chronic obstructive pulmonary disease.Copyright © 2022 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

基金：
UniversitiesGiessen and Marburg Lung Center, German Center for Lung Research, University Hospital Giessen and Marburg research funding according to Article 2,Section 3 of the Cooperation Agreement, and theDeutsche Forschungsgemeinschaft (German Research Foundation)-SFB 1021 (project identifier 197785619), KFO 309 (project identifier 284237345), and SK 317/1-1 (project identifier 428518790), and the Foundation for Pathobiochemistry and Molecular Diagnostics (to C.S.).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类 | 1 区 医学
小类 | 1 区 过敏 1 区 免疫学
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 过敏 1 区 免疫学
JCR分区：
出版当年[2021]版：
Q1 ALLERGY Q1 IMMUNOLOGY
最新[2023]版：
Q1 ALLERGY Q1 IMMUNOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者：
第一作者单位： [1]Institute of Laboratory Medicine and Pathobiochemistry, Philipps University Marburg [2]Universities of Giessen and Marburg Lung Center (UGMLC), Philipps University Marburg [*1]Institute of Laboratory Medicine and Pathobiochemistry, Molecular Diagnostics, Philipps University Marburg, Baldingerstr. 35043, Marburg
通讯作者：
通讯机构： [1]Institute of Laboratory Medicine and Pathobiochemistry, Philipps University Marburg [2]Universities of Giessen and Marburg Lung Center (UGMLC), Philipps University Marburg [*1]Institute of Laboratory Medicine and Pathobiochemistry, Molecular Diagnostics, Philipps University Marburg, Baldingerstr. 35043, Marburg
推荐引用方式(GB/T 7714)：
Skevaki Chrysanthi,Chinthrajah R Sharon,Fomina Daria,et al.Comorbidity defines asthmatic patients' risk of COVID-19 hospitalization: A global perspective[J].JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY.2023,151(1):110-117.doi:10.1016/j.jaci.2022.09.039.
APA：
Skevaki Chrysanthi,Chinthrajah R Sharon,Fomina Daria,Rohde Gernot,Cao Shu...&Renz Harald.(2023).Comorbidity defines asthmatic patients' risk of COVID-19 hospitalization: A global perspective.JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY,151,(1)
MLA：
Skevaki Chrysanthi,et al."Comorbidity defines asthmatic patients' risk of COVID-19 hospitalization: A global perspective".JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY 151..1(2023):110-117

相关文献

[1]Tiotropium In Early Chronic Obstructive Pulmonary Disease Patients in China [2]Heterogeneities and impact profiles of early chronic obstructive pulmonary disease status: findings from the China Pulmonary Health Study [3]Expert consensus on acute exacerbation of chronic obstructive pulmonary disease in the People's Republic of China [4]Evaluation of Blood Markers at Admission for Predicting Community Acquired Pneumonia in Chronic Obstructive Pulmonary Disease [5]Clinical Characteristics and Outcomes of Patients with Severe COVID-19 and Chronic Obstructive Pulmonary Disease (COPD) [6]Perception of circadian variation of symptoms in Chinese patients with chronic obstructive pulmonary disease [7]International expert consensus on diagnosis and treatment of lung cancer complicated by chronic obstructive pulmonary disease [8]MFG-E8, a clearance glycoprotein of apoptotic cells, as a new marker of disease severity in chronic obstructive pulmonary disease [9]Endoplasmic reticulum stress: a vital process and potential therapeutic target in chronic obstructive pulmonary disease [10]Increased Circulating Autoantibodies Levels of IgG, IgA, IgM Against Cytokeratin 18 and Cytokeratin 19 in Chronic Obstructive Pulmonary Disease

资源点击量：426 今日访问量：0 总访问量：410 更新日期：2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有：重庆聚合科技有限公司 渝ICP备12007440号-3 地址：重庆市两江新区泰山大道西段8号坤恩国际商务中心16层（401121）